The confidential European Union draft for revisions to general pharmaceutical legislation has leaked. The first piece of news is that the Regulatory Scrutiny Board, an independent EU body that assesses proposed policies, laws, or actions, has significant “reservations.” And, indeed, some of the reservations are frightening when it comes to the future of healthcare technology innovation in Europe.
Read Full Article »
